Rehabilitation Hospital affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China
Fujian Key Laboratory of Rehabilitation Technology, Fuzhou, Fujian, China.
BMJ Open. 2022 Nov 15;12(11):e067280. doi: 10.1136/bmjopen-2022-067280.
This study aims to systematically evaluate the effects of Baduanjin on motor function, balance and gait in patients with Parkinson's disease (PD).
Systematic review and meta-analysis.
All eligible randomised controlled trials (RCTs) published in the English and Chinese language were included.
Ten electronic databases were systematically searched, from inception to 17 March 2022: PubMed, Web of Science, Cochrane Library, Embase, EBSCOhost, OVID, SinoMed, China National Knowledge Infrastructure, Wanfang Data and China Science Journal Database (VIP).
Methodological quality assessment and meta-analysis were performed for the included studies using the Cochrane Review Manager V.5.4 software.
Ten RCTs with 804 participants were included. The results revealed the following: (1) Baduanjin significantly improved the motor function of patients with PD, based on the Unified Parkinson's Disease Rating Scale Part III (mean difference, MD -5.37, 95% CI -8.96 to -1.78, p=0.003) and Fugl-Meyer Assessment of Lower Extremity (MD 5.39, 95% CI 2.71 to 8.07, p<0.0001); (2) Baduanjin significantly improved the ability of balance of patients with PD, based on the Berg Balance Scale (MD 4.40, 95% CI 3.08 to 5.73, p<0.00001); (3) Baduanjin significantly improved the gait of patients with PD, based on the 6 min walk distance (MD 21.62, 95% CI 11.14 to 32.10, p<0.0001). After the further subgroup and sensitivity analyses, the heterogeneity was identified to be potentially due to the different degrees of disease severity in patients with PD and the difference in Baduanjin intervention durations.
The analysis of this systematic evaluation indicates that Baduanjin might have a positive effect in improving the motor function, balance and gait of patients with PD. However, due to the quantity and clinical heterogeneity limitations of the included studies, this conclusion still warrants more high-quality and multicentre RCTs for further verification.
本研究旨在系统评估八段锦对帕金森病（PD）患者运动功能、平衡和步态的影响。
系统评价和荟萃分析。
纳入所有发表于英文和中文的合格随机对照试验（RCT）。
从建库至 2022 年 3 月 17 日，系统检索了 10 个电子数据库：PubMed、Web of Science、Cochrane 图书馆、Embase、EBSCOhost、OVID、SinoMed、中国知网、万方数据和中国科技期刊数据库（VIP）。
使用 Cochrane Review Manager V.5.4 软件对纳入研究进行方法学质量评估和荟萃分析。
纳入 10 项 RCT 共 804 名参与者。结果显示：（1）基于统一帕金森病评定量表第 3 部分（MD-5.37，95%CI-8.96 至-1.78，p=0.003）和 Fugl-Meyer 评估下肢（MD 5.39，95%CI 2.71 至 8.07，p<0.0001），八段锦显著改善 PD 患者的运动功能；（2）基于 Berg 平衡量表（MD 4.40，95%CI 3.08 至 5.73，p<0.00001），八段锦显著改善 PD 患者的平衡能力；（3）基于 6 分钟步行距离（MD 21.62，95%CI 11.14 至 32.10，p<0.0001），八段锦显著改善 PD 患者的步态。进一步的亚组和敏感性分析后，发现异质性可能归因于 PD 患者疾病严重程度的不同和八段锦干预时间的差异。
本系统评价分析表明，八段锦可能对改善 PD 患者的运动功能、平衡和步态有积极作用。然而，由于纳入研究的数量和临床异质性限制，这一结论仍需要更多高质量和多中心 RCT 进一步验证。
